Tag Archives: Chris Schott

J.P. Morgan Sticks to Their Hold Rating for Pfizer (PFE)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $46. The company’s shares opened today at $43.09. According to TipRanks.com, Schott has 0 stars on 0-5 star

Pfizer (PFE) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $46. The company’s shares closed yesterday at $39.38. According to TipRanks.com, Schott has 0 stars on 0-5 star

J.P. Morgan Reiterates a Buy Rating on Momenta Pharma

In a report released today, Chris Schott from J.P. Morgan reiterated a Buy rating on Momenta Pharma (NASDAQ: MNTA), with a price target of $18. The company’s shares opened today at $11.05. Schott said: “We are updating our model following

Zoetis Receives a Hold from J.P. Morgan

J.P. Morgan analyst Chris Schott reiterated a Hold rating on Zoetis (NYSE: ZTS) today and set a price target of $53. The company’s shares opened today at $50.17. According to TipRanks.com, Schott is a 1-star analyst with an average return

Eli Lilly & Co Received its Third Buy in a Row

After Leerink Swann and Credit Suisse assigned a Buy rating to Eli Lilly & Co in the last month, the company received another Buy, this time from J.P. Morgan. Analyst Chris Schott upgraded Eli Lilly & Co (NYSE: LLY) to

AbbVie was Downgraded to a Hold Rating at J.P. Morgan

J.P. Morgan analyst Chris Schott downgraded AbbVie (NYSE: ABBV) to Hold today. The company’s shares closed yesterday at $64.97, close to its 52-week high of $68.12. According to TipRanks.com, Schott is a 1-star analyst with an average return of -2.1%